Corvus Pharmaceuticals, Inc. financial data

Symbol
CRVS on Nasdaq
Industry
Pharmaceutical Preparations
Location
863 Mitten Road, Suite 102, Burlingame, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 25, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 165 % -62.7%
Debt-to-equity 79.3 % +344%
Return On Equity -192 % -223%
Return On Assets -107 % -112%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.1M shares +38.9%
Common Stock, Shares, Outstanding 67.9M shares +38.5%
Entity Public Float 69M USD -18.1%
Common Stock, Value, Issued 7K USD +40%
Weighted Average Number of Shares Outstanding, Basic 61M shares +27%
Weighted Average Number of Shares Outstanding, Diluted 61M shares +27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 19.4M USD +17.3%
General and Administrative Expense 8.16M USD +18.6%
Operating Income (Loss) -27.5M USD -17.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -62.3M USD -130%
Earnings Per Share, Basic -1.02 USD/shares -82.1%
Earnings Per Share, Diluted -1.02 USD/shares -82.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.74M USD -30.7%
Cash, Cash Equivalents, and Short-term Investments 52M USD +91.9%
Accounts Receivable, after Allowance for Credit Loss, Current 75K USD +188%
Other Assets, Current 548K USD +149%
Assets, Current 54.4M USD +94.6%
Property, Plant and Equipment, Net 151K USD -36%
Operating Lease, Right-of-Use Asset 1.18M USD +2.44%
Other Assets, Noncurrent 632K USD +610%
Assets 68.9M USD +51.3%
Accounts Payable, Current 2.58M USD +69.3%
Employee-related Liabilities, Current 610K USD -18.8%
Accrued Liabilities, Current 3.73M USD -6.17%
Liabilities, Current 35.4M USD +415%
Operating Lease, Liability, Noncurrent 937K USD
Liabilities 36.3M USD +429%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.29M USD -33.2%
Retained Earnings (Accumulated Deficit) -397M USD -18.6%
Stockholders' Equity Attributable to Parent 32.6M USD -15.8%
Liabilities and Equity 68.9M USD +51.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.16M USD +36.4%
Net Cash Provided by (Used in) Investing Activities 4.6M USD
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 67.9M shares +38.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.16M USD -47.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.74M USD -30.7%
Deferred Tax Assets, Valuation Allowance 90.5M USD +9.11%
Deferred Tax Assets, Gross 90.9M USD +9.11%
Operating Lease, Liability 354K USD
Payments to Acquire Property, Plant, and Equipment 34K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.6M USD -128%
Lessee, Operating Lease, Liability, to be Paid 358K USD
Property, Plant and Equipment, Gross 4.78M USD -3.16%
Operating Lease, Liability, Current 185K USD -86.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.43M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 64.1M USD +8.04%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 13.1M USD +2.44%
Operating Lease, Payments 1.88M USD +5.98%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 23K USD -59.6%
Share-based Payment Arrangement, Expense 3M USD +39.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%